Health
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
NEW YORK, December 06, 2025--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no t
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/7acf403f8a83567b648b969da51d6997"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9LJXXIRUiryfMqvyYmdpHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7acf403f8a83567b648b969da51d6997","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and published in Blood","length":142,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":142,"olType":false},{"type":"text","content":"NEW YORK, December 06, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no treatment-related lab monitoring.","length":549,"tagName":"p"},{"type":"text","content":"The findings were shared today in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando and published in Blood.","length":168,"tagName":"p"},{"type":"text","content":"Inhibitors, or antibodies, which neutralize factor replacement therapies and render them ineffective, may develop in people living with hemophilia.1 Inhibitors can be diagnosed with a blood test.2 Of the more than 800,000 people in the world living with hemophilia A or hemophilia B, approximately 20% of people with hemophilia A and 3% of people with hemophilia B are unable to continue taking factor replacement therapies because they develop inhibitors to FVIII (factor VIII) and FIX (factor IX), respectively, and these therapies no longer prevent or stop bleeding episodes.2,3","length":581,"tagName":"p"},{"type":"text","content":""The emergence of inhibitors poses significant treatment challenges and can increas...